Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, Belkaid W, Richard C, Messaoudene M, Cvetkovic L, Kazandjian S, Tehfe M, Florescu M, Jao K, Daaboul N, Owen S, Shieh B, Agulnik J, Cohen V, Charbonneau C, Marcoux N, Blais N, Leighl NB, Bradbury PA, Liu G, Shepherd FA, Bahig H, Routy B, Sacher A, Elkrief A. Desilets A, et al. Among authors: blais n. Eur J Cancer. 2021 Jan;142:83-91. doi: 10.1016/j.ejca.2020.10.008. Epub 2020 Nov 24. Eur J Cancer. 2021. PMID: 33242835
Emepepimut-S for non-small cell lung cancer.
Corrales-Rodriguez L, Blais N, Soulières D. Corrales-Rodriguez L, et al. Among authors: blais n. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7. doi: 10.1517/14712598.2011.592490. Epub 2011 Jun 21. Expert Opin Biol Ther. 2011. PMID: 21689064
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit. Ellis PM, et al. Among authors: blais n. Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439692 Clinical Trial.
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH. Chiappori AA, et al. Among authors: blais n. Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2. Ann Oncol. 2015. PMID: 25467017 Free PMC article. Clinical Trial.
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q. Ellis PM, et al. Among authors: blais n. Clin Lung Cancer. 2015 Nov;16(6):457-65. doi: 10.1016/j.cllc.2015.05.010. Epub 2015 Jun 2. Clin Lung Cancer. 2015. PMID: 26100229 Clinical Trial.
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V. Melosky B, et al. Among authors: blais n. Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9. Curr Oncol. 2016. PMID: 27330348 Free PMC article.
182 results